Shares of Amgen Inc. AMGN inched 0.19% higher to $264.49 Tuesday, on what proved to be an all-around positive trading session ...
Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options ...
Amgen's leukemia drug Blincyto infringes patents owned by Germany's Lindis Biotech, a Delaware federal jury said in a verdict ...
Hosted on MSN1d
Here's Why Amgen (AMGN) Gained But Lagged the Market TodayThe most recent trading session ended with Amgen (AMGN) standing at $264, reflecting a +0.24% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.73%.
StockNews.com lowered shares of Amgen (NASDAQ:AMGN – Free Report) from a strong-buy rating to a buy rating in a research ...
Novo Nordisk's CagriSema shows 22.7% weight loss in Phase 3 trials, while tolerability concerns grow. MariTide offers ...
Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly ...
Amgen, a biotechnology company, announced last week that it will invest $1 billion in expanding its manufacturing facility in ...
In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other dividend stocks. Dividend-focused investors are often drawn to stocks with high yields ...
Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The company’s ...
UBS analyst Trung Huynh says Novo Nordisk’s CagriSema Phase 3 topline obesity data “underwhelmed,” a positive read-through to Eli Lilly and Amgen . CagriSema achieved an ave ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback